M D Berry

Summary

Affiliation: Brandon University
Country: Canada

Publications

  1. ncbi The potential of trace amines and their receptors for treating neurological and psychiatric diseases
    M D Berry
    Department of Chemistry, Brandon University, 270, 18th Street, Brandon, Manitoba, Canada, R7A 6A9
    Rev Recent Clin Trials 2:3-19. 2007
  2. ncbi Molecular dynamics-based simulation of trace amine membrane permeability
    Mark D Berry
    Department of Chemistry, Brandon University, 270 18th Street, Brandon, MB, R7A 6A9, Canada
    J Neural Transm 118:1119-28. 2011
  3. ncbi The effects of pargyline and 2-phenylethylamine on D1-like dopamine receptor binding
    Mark D Berry
    Department of Chemistry, Brandon University, Brandon, MB, R7A 6A9, Canada
    J Neural Transm 118:1115-8. 2011
  4. ncbi Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders
    Mark D Berry
    ALviva Biopharmaceuticals Inc, Saskatoon, Sask
    J Psychiatry Neurosci 29:337-45. 2004
  5. ncbi Glyceraldehyde-3-phosphate dehydrogenase and apoptosis
    M D Berry
    Alviva Biopharmaceuticals, Inc, Suite 112C, 116, Research Drive, Innovation Place, Saskatoon, Saskatchewan, Canada
    J Neurosci Res 60:150-4. 2000
  6. ncbi N8-acetyl spermidine protects rat cerebellar granule cells from low K+-induced apoptosis
    M D Berry
    Neuropsychiatry Research Unit, University of Saskatchewan, Saskatoon, Canada
    J Neurosci Res 55:341-51. 1999
  7. ncbi Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents
    P C Ashe
    ALviva Biopharmaceuticals Inc, Saskatoon, Saskatchewan, Canada
    Prog Neuropsychopharmacol Biol Psychiatry 25:691-707. 2001
  8. ncbi Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases
    M D Berry
    ALviva Biopharmaceuticals Inc, 218-111 Research Drive, Saskatoon, SK, Canada S7N 3R2
    Neurotoxicol Teratol 24:667-73. 2002
  9. ncbi Loss of mitochondrial membrane potential is dependent on the apoptotic program activated: prevention by R-2HMP
    D Zhang
    Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Neurosci Res 58:284-92. 1999
  10. ncbi Prolongation of life in an experimental model of aging in Drosophila melanogaster
    R G Jordens
    Neuropsychiatry Research Unit, University of Saskatchewan, Saskatoon, Canada
    Neurochem Res 24:227-33. 1999

Detail Information

Publications12

  1. ncbi The potential of trace amines and their receptors for treating neurological and psychiatric diseases
    M D Berry
    Department of Chemistry, Brandon University, 270, 18th Street, Brandon, Manitoba, Canada, R7A 6A9
    Rev Recent Clin Trials 2:3-19. 2007
    ..In addition, recent evidence linking trace amines to the development of drug dependence will be discussed...
  2. ncbi Molecular dynamics-based simulation of trace amine membrane permeability
    Mark D Berry
    Department of Chemistry, Brandon University, 270 18th Street, Brandon, MB, R7A 6A9, Canada
    J Neural Transm 118:1119-28. 2011
    ..The adopted simulation methods failed to yield diffusion coefficients in the core region indicating that further work will be required to accurately predict permeability coefficients for trace amines passing through membranes...
  3. ncbi The effects of pargyline and 2-phenylethylamine on D1-like dopamine receptor binding
    Mark D Berry
    Department of Chemistry, Brandon University, Brandon, MB, R7A 6A9, Canada
    J Neural Transm 118:1115-8. 2011
    ..It is concluded that the effect of pargyline does not involve elevation of endogenous PE, and PE effects on dopaminergic neurotransmission are not due to altered D1-like receptor binding...
  4. ncbi Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders
    Mark D Berry
    ALviva Biopharmaceuticals Inc, Saskatoon, Sask
    J Psychiatry Neurosci 29:337-45. 2004
    ..These compounds, one of which is currently being tested in late-stage Phase II clinical trials as a disease-modifying therapy for Parkinson's disease, have potential utility in the treatment of human neurodegenerative conditions...
  5. ncbi Glyceraldehyde-3-phosphate dehydrogenase and apoptosis
    M D Berry
    Alviva Biopharmaceuticals, Inc, Suite 112C, 116, Research Drive, Innovation Place, Saskatoon, Saskatchewan, Canada
    J Neurosci Res 60:150-4. 2000
    ..This review summarizes the evidence implicating GAPDH in the initiation of one or more apoptotic cascades. The possible functions of GAPDH in the nucleus which could result in the initiation of apoptosis are also discussed...
  6. ncbi N8-acetyl spermidine protects rat cerebellar granule cells from low K+-induced apoptosis
    M D Berry
    Neuropsychiatry Research Unit, University of Saskatchewan, Saskatoon, Canada
    J Neurosci Res 55:341-51. 1999
    ..The lack of effect on basal apoptosis provides evidence of at least two forms of p53-independent apoptosis that can be regulated independently...
  7. ncbi Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents
    P C Ashe
    ALviva Biopharmaceuticals Inc, Saskatoon, Saskatchewan, Canada
    Prog Neuropsychopharmacol Biol Psychiatry 25:691-707. 2001
    ..Recent evidence suggests that the progressive course of schizophrenia is associated with ongoing neurodegenerative processes. Changes in brain derived neurotrophic factor (BDNF) may explain the various changes observed in schizophrenia...
  8. ncbi Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases
    M D Berry
    ALviva Biopharmaceuticals Inc, 218-111 Research Drive, Saskatoon, SK, Canada S7N 3R2
    Neurotoxicol Teratol 24:667-73. 2002
    ..These compounds have been shown to be active through an interaction with the same binding site as R-deprenyl and CGP 3466. This site is suggested to be the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH)...
  9. ncbi Loss of mitochondrial membrane potential is dependent on the apoptotic program activated: prevention by R-2HMP
    D Zhang
    Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Neurosci Res 58:284-92. 1999
    ..The antiapoptotic drug R-N-2-heptyl-N-methylpropargylamine hydrochloride (R-2HMP) reversed this loss of mitochondrial membrane potential in Ara-c-induced apoptosis; the effect was antagonized by the S-2HMP...
  10. ncbi Prolongation of life in an experimental model of aging in Drosophila melanogaster
    R G Jordens
    Neuropsychiatry Research Unit, University of Saskatchewan, Saskatoon, Canada
    Neurochem Res 24:227-33. 1999
    ..5-1 ng/fly/day, led to a significant increase in mean and maximal life-span of galactose-treated, but not control flies. This effect was seen in both wild-type and mutant flies...
  11. ncbi Apoptosis and human neurodegenerative diseases
    Mark D Berry
    ALviva Biopharmaceuticals Inc, 218-111, Research Drive, S7N 3R2, Saskatoon, Saskatchewan, Canada
    Prog Neuropsychopharmacol Biol Psychiatry 27:197-8. 2003
  12. ncbi Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators
    Mark D Berry
    ALviva Biopharmaceuticals Inc, Saskatoon, Saskatchewan, Canada
    J Neurochem 90:257-71. 2004
    ..These effects are seen as an altered neuronal sensitivity to monoamine neurotransmitters, with no change in neuronal excitability in the absence of neurotransmitter...